Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973250 | 0.82 | GSK3B (0.58) | GSK3BDAOIKBKB | |
| SCHEMBL26663876 | 0.77 | DAO (0.50) | DAOCA2MAPTSMN1; SMN2IKBKB | |
| SCHEMBL10638896 | 0.76 | DAO (0.35) | GSK3BDAOIKBKB | |
| SCHEMBL10511018 | 0.73 | DAO (0.61) | RAB9AGSK3BDAOCA2SMN1; SMN2 | |
| SCHEMBL25819048 | 0.72 | GSK3B (0.40) | RAB9AGSK3BDAOCA2MAPT | |
| SCHEMBL10513627 | 0.72 | DAO (0.59) | GSK3BDAOCA2MAPTSMN1; SMN2 | |
| SCHEMBL21963268 | 0.68 | CA2 (0.71) | CA2 | |
| SCHEMBL12763640 | 0.67 | — | — | |
| SCHEMBL11382828 | 0.66 | MAPT (0.50) | MAPTSMN1; SMN2L3MBTL1ATMBRD4 | |
| SCHEMBL1146988 | 0.66 | RAB9A (0.71) | PGRRAB9AGSK3BCA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| CN-1117091-C | Substd. isoxazolylthiophene compounds | TAISHO PHARMACEUTICAL CO LTD (JP) | 2003-08-06 | — | — | CN | disclosed |
| CN-1321156-A | Substd. isoxazolylthiophene compounds | TAISHO PHARMACEUTICAL CO LTD (JP) | 2001-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | PGR 4331/4885RAB9A 690/4885GSK3B 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.